UBS AM
ARQT icon

UBS AM’s Arcutis Biotherapeutics ARQT Stock Holding History

UBS AM’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.06M Sell
231,186
-5,985
-3% -$139K ﹤0.01% 1513
2026
Q1 		$5.59M Buy
237,171
+5,437
+2% +$139K ﹤0.01% 1517
2025
Q4 		$6.73M Sell
231,734
-12,281
-5% -$314K ﹤0.01% 1306
2025
Q3 		$4.6M Sell
244,015
-160,721
-40% -$2.53M ﹤0.01% 1408
2025
Q2 		$5.67M Buy
404,736
+125,689
+45% +$1.76M ﹤0.01% 1653
2025
Q1 		$4.36M Sell
279,047
-1,053
-0.4% -$14.8K ﹤0.01% 1640
2024
Q4 		$3.9M Buy
280,100
+3,409
+1% +$37.4K ﹤0.01% 1732
2024
Q3 		$2.57M Buy
276,691
+2,912
+1% +$28.7K ﹤0.01% 1918
2024
Q2 		$2.55M Buy
+273,779
New +$2.48M ﹤0.01% 1867
2023
Q4 		– Sell
-81,080
Closed -$431K – 2545
2023
Q3 		$431K Buy
81,080
+21,465
+36% +$183K ﹤0.01% 2349
2023
Q2 		$656K Hold
59,615
– – ﹤0.01% 2214
2023
Q1 		$656K Buy
59,615
+25,899
+77% +$375K ﹤0.01% 2214
2022
Q4 		$499K Buy
33,716
+14,616
+77% +$255K ﹤0.01% 2177
2022
Q3 		$365K Sell
19,100
-10,872
-36% -$246K ﹤0.01% 2451
2022
Q2 		$639K Hold
29,972
– – ﹤0.01% 2194
2022
Q1 		$577K Hold
29,972
– – ﹤0.01% 2414
2021
Q4 		$622K Hold
29,972
– – ﹤0.01% 2458
2021
Q3 		$716K Hold
29,972
– – ﹤0.01% 2331
2021
Q2 		$818K Buy
29,972
+8,772
+41% +$247K ﹤0.01% 2323
2021
Q1 		$613K Buy
+21,200
New +$662K ﹤0.01% 2317

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS AM's ARQT Position: Q2 2026 in Review

UBS AM reduced its Arcutis Biotherapeutics (ARQT) stake by 2.5% in Q2 2026, selling an estimated $139K and leaving 231,186 shares worth $6.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1513.

UBS AM first reported a position in ARQT in Q1 2021 and has held it in 20 quarters since. The position peaked at $6.73M in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • UBS AM held 231,186 shares of Arcutis Biotherapeutics worth $6.06M as of Q2 2026.
  • UBS AM sold 5,985 Arcutis Biotherapeutics shares in Q2 2026, an estimated $139K.
  • Arcutis Biotherapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1513 holding.
  • UBS AM first reported a position in Arcutis Biotherapeutics in Q1 2021 and has held it in 20 quarters since.
  • UBS AM's Arcutis Biotherapeutics position peaked at $6.73M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.